The analysis presented on the website is based on the data from newest edition (2025).

You can also preview the analysis from previous editions (for 2022-20223 editions also in SK, HU and CS).

Disease landscape

Acute myeloid leukemia (AML)

Significant constraints in access to AML diagnosis and treatment have been identified in the Visegrád (V4) countries. The obtained scores place the indicator for AML at a medium level among all assessed diseases. Results vary moderately from state to state - the difference between the highest and the lowest score is 17 points. The main reason for the unsatisfactory performance of the V4 group in AML is limited access to novel drugs in all the V4 countries due to the lack of reimbursement or strict reimbursement criteria. Despite these limitations of systemic reimbursement for all included drugs for AML patients, the proportion of patients treated with a subset of selected drugs is high. The area that pulls the total score up in all countries is the relatively good access to AML diagnosis in the region and relatively decent time to availability (compared to other diseases).

As part of the V4 GAP project in the 2025 edition, we conducted a methodological update for this disease, which included change in selected drugs and the incorporation of US NCCN guidelines for haemato-oncological malignancies. For details, take a look at this document.

Cross-Country

General GAP for AML

Poland

65

Hungary

57

Czechia

67

Slovakia

50

Compliance with guidelines

Positive recommendations for 10 AML drugs were found in analyzed clinical practice guidelines. Between 3 and 6 of these are available for AML patients in the individual V4 countries.

From registration to reimbursement

Population burden

DALY* - Rate per 100k

*disability adjusted life-years

Target population

Selected drugs

Drug access

Number of patients treated (2023)

Drug access

POPULATION treated - selected drugs (%)*

*percentage of the population potentially eligible for treatment with the selected drugs: Rydapt, Venclyxto, Xospata, Tibsovo, Vanflyta

Main issues

  • The average time to reimbursement for AML drugs in the V4 countries is 2.8 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 1.9 years.
  • The use of selected new drugs in the target population is high, ranging from more than 50% in the Czech Republic and Hungary to almost 90% in Slovakia.
  • DALY (disability adjusted life-years) burden related to AML in the V4 countries is lower (up to 10%) than the European Union average.

Project

We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).